PMID- 37238990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230530
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 5
DP  - 2023 Apr 28
TI  - Humoral Immune Response after COVID-19 mRNA Vaccination in Patients with Liver 
      Cirrhosis: A Prospective Real-Life Single Center Study.
LID - 10.3390/biomedicines11051320 [doi]
LID - 1320
AB  - Coronavirus-disease-2019 (COVID-19) mRNA vaccination effectively reduces 
      mortality and morbidity in cirrhotic patients, but the immunogenicity and safety 
      of vaccination have been partially characterized. The study aimed to evaluate 
      humoral response, predictive factors, and safety of mRNA-COVID-19 vaccination in 
      cirrhotic patients compared to healthy subjects. A prospective, single-center, 
      observational study enrolled consecutive cirrhotic patients who underwent 
      mRNA-COVID-19 vaccination from April to May 2021. Anti-spike-protein (anti-S) and 
      nucleocapsid-protein (anti-N) antibodies were evaluated before the first (T0) and 
      the second (T1) doses and 15 days after completing the vaccination. An age and 
      sex-matched healthy reference group was included. The incidence of adverse events 
      (AEs) was assessed. In total, 162 cirrhotic patients were enrolled, 13 were 
      excluded due to previous SARS-CoV-2 infection; therefore, 149 patients and 149 
      Health Care Workers (HCWs) were included in the analysis. The seroconversion rate 
      was similar in cirrhotic patients and HCWs at T1 (92.5% vs. 95.3%, p = 0.44) and 
      T2 (100% in both groups). At T2, anti-S-titres were significantly higher in 
      cirrhotic patients compared to HCWs (2776.6 vs. 1756 BAU/mL, p < 0.001]. Male sex 
      (beta = -0.32 [-0.64, -0.04], p = 0.027) and past-HCV-infection (beta = -0.31 [-0.59, 
      -0.04], p = 0.029) were independent predictors of lower anti-S-titres on 
      multiple-gamma-regression-analysis. No severe AEs occurred. The COVID-19-mRNA 
      vaccination induces a high immunization rate and anti-S-titres in cirrhotic 
      patients. Male sex and past-HCV infection are associated with lower 
      anti-S-titres. The COVID-19-mRNA vaccination is safe.
FAU - Biliotti, Elisa
AU  - Biliotti E
AUID- ORCID: 0000-0002-4540-1815
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Caioli, Alessandro
AU  - Caioli A
AUID- ORCID: 0000-0003-2097-9116
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Sorace, Chiara
AU  - Sorace C
AD  - Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy.
FAU - Lionetti, Raffaella
AU  - Lionetti R
AUID- ORCID: 0000-0003-2827-4591
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Milozzi, Eugenia
AU  - Milozzi E
AUID- ORCID: 0009-0001-1424-4618
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Taibi, Chiara
AU  - Taibi C
AUID- ORCID: 0000-0003-2556-1560
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Visco Comandini, Ubaldo
AU  - Visco Comandini U
AUID- ORCID: 0000-0003-0460-8024
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Maggi, Fabrizio
AU  - Maggi F
AUID- ORCID: 0000-0001-7489-5271
AD  - Laboratory of Virology, National Institute for Infectious Diseases Lazzaro 
      Spallanzani IRCCS, 00149 Rome, Italy.
FAU - Puro, Vincenzo
AU  - Puro V
AUID- ORCID: 0000-0003-0291-4490
AD  - Risk Management Unit, National Institute for Infectious Diseases Lazzaro 
      Spallanzani IRCCS, 00149 Rome, Italy.
FAU - D'Offizi, Gianpiero
AU  - D'Offizi G
AUID- ORCID: 0000-0002-0091-3585
AD  - Infectious Diseases Hepatology Department, National Institute for Infectious 
      Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230428
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10215518
OTO - NOTNLM
OT  - COVID-19
OT  - anti-spike antibodies titres
OT  - cirrhotic patients
OT  - humoral response
OT  - mRNA vaccination
OT  - male sex
OT  - past HCV infection
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/27 09:42
MHDA- 2023/05/27 09:43
PMCR- 2023/04/28
CRDT- 2023/05/27 01:08
PHST- 2023/03/24 00:00 [received]
PHST- 2023/04/18 00:00 [revised]
PHST- 2023/04/25 00:00 [accepted]
PHST- 2023/05/27 09:43 [medline]
PHST- 2023/05/27 09:42 [pubmed]
PHST- 2023/05/27 01:08 [entrez]
PHST- 2023/04/28 00:00 [pmc-release]
AID - biomedicines11051320 [pii]
AID - biomedicines-11-01320 [pii]
AID - 10.3390/biomedicines11051320 [doi]
PST - epublish
SO  - Biomedicines. 2023 Apr 28;11(5):1320. doi: 10.3390/biomedicines11051320.